Osteoporosis: Romosozumab versus teriparatide
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Rheumatology"
DOI: 10.1038/nrrheum.2017.135
Abstract: The effect of two bone-forming agents — the anti-slerostin antibody romosozumab and the recombinant PTH teriparatide — were compared in an open-label, randomized phase III study involving 436 women with postmenopausal osteoporosis who had been… read more here.
Keywords: romosozumab versus; osteoporosis romosozumab; rheumatology; romosozumab ... See more keywords